Qianhai Xino-backed Akeso Biopharma will use the series B capital to build a drug manufacturing facility in China.

Shuanglu Pharma-backed CF PharmTech has raised $65m in a series D round led by fund managed by China state-owned State Development & Investment Corporation.

GV-backed Freenome has raised $7m in a series A extension led by Section 32, the venture capital firm launched by former GV chief executive Bill Maris.

Amgen Ventures and Alexandria Real Estate Equities have invested $6m in GNS Healthcare, which already counts Celgene, Cambia Health and Mitsui as investors.

Boston Scientific was among the investors that provided $14.1m in series C-1 funding for the medical device developer, taking its total funding to about $46m.

Strategic investors Aetna and Horizon Healthcare Services were among the investors in a $36.6m round that took AbleTo's total funding to more than $57m.

University of Massachusetts Medical School spinoff Apic Bio has raised seed capital from The Alpha-1 Project as it looks to develop a treatment for Alpha-1 Antitrypsin deficiency.

The skin disease therapy developer has filed for a $34.5m initial public offering, days after raising $11.3m in a Sun Pharmaceutical Industries-led round.